Long-acting VIP formulations for the treatment of chronic inflammatory diseases

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$600,000.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI082723-01
Award Id:
93398
Agency Tracking Number:
AI082723
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
720 BROADWAY, STE 511, SEATTLE, WA, 98122
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
167580682
Principal Investigator:
SANDRA REICHSTETTER
(206) 568-1494
SREICHSTETTER@PHARMAIN.COM
Business Contact:
ELIJAH BOLOTIN
() -
ebolotin@pharmain.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that are only poorly controlled. Vasoactive int estinal peptide (VIP) is an immunomodulatory peptide that induces regulatory T-cells and anti-inflammatory cytokine responses and has shown efficacy in numerous rodent models of autoimmune diseases with predominant TH1-type immune responses. Use of VIP in humans is severely hindered by its short in vivo half-life, and the therapeutic window is limited by the vasodilatory properties of this peptide that can cause an unsafe drop in blood pressure upon injection. Formulating VIP into a nanocarrier can improve both properties as the binding to the nanocarrier sequesters it from degrading enzymes and excretion by the kidney. The binding of VIP to a nanocarrier also decreases the concentration of free VIP in serum, thereby decreasing the blood pressure drop and in creasing the therapeutic window. In this application two different nanocarriers will be compared in their ability to formulate VIP for the treatment of chronic inflammatory diseases. The nanocarriers are a Protected Graft Copolymer (PGC), in which a poly-l ysine backbone is grafted with polyethylene glycol (PEG) side chains. The load-molecule will bind to specific residues between the PEG-side chains. The other nanocarrier consists of a sterically stabilized micelle (SSM). These different nanocarrier-VIP for mulations will be compared in terms of efficacy in collagen induced arthritis, a mouse model of rheumatoid arthritis. Additionally, the pharmacokinetics of the different nanocarrier-VIP formulations will be determined. Toxicity will be tested using non-inv asive blood pressure monitors that measure peripheral arterial pressure in the tail with an inflatable tail cuff, in addition to monitoring general parameters of health (behavior, appearance, diarrhea etc). PUBLIC HEALTH RELEVANCE: Vasoactive intest inal peptide (VIP) is a hormone in the human body that can be used for the treatment of autoimmune diseases in animal models. Rapid degradation and side effects at high dose have so far limited VIP use in humans. In this project VIP will be formulated into forms that will deal with these problems that will allow its universal use in many human diseases.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government